Evidence map›Paper›PMID 36143940›Full record

ArticleMedicina (Kaunas, Lithuania)2022

Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers.

Yousef M Al-Saraireh, Fatemah O F O Alshammari, Anas O Satari, Yanal S Al-Mahdy, Ghadeer H Almuhaisen, Omar H Abu-Azzam, Ala N Uwais, Seham M Abufraijeh, Ahlam M Al-Kharabsheh, Sa'ed M Al-Dalain and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Improved methods for the detection of heme and protoporphyrin IX adducts and quantification of heme B from cytochrome P450 containing systems.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Yousef M Al-SarairehDepartment of Pharmacology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Fatemah O F O AlshammariDepartment of Medical Lab Technology, Faculty of Health Sciences, The Public Authority for Applied Education and Training, Shuwaikh 15432, Kuwait.
Anas O SatariFaculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Yanal S Al-MahdyFaculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.ORCID 0000-0002-1724-0364
Ghadeer H AlmuhaisenDepartment of Microbiology and Pathology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Omar H Abu-AzzamDepartment of Obstetrics and Gynecology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Ala N UwaisDepartment of Obstetrics and Gynecology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Seham M AbufraijehDepartment of Obstetrics and Gynecology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Ahlam M Al-KharabshehDepartment of Obstetrics and Gynecology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Sa'ed M Al-DalainDepartment of Pharmacology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Aiman Al-QtaitatDepartment of Anatomy and Histology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Fatima Al-TarawnehDepartment of Allied Medical Sciences, Faculty of Al-Karak, Al-Balqa Applied University, P.O. Box 7, Al-Karak 61710, Jordan.
Jehad M Al ShuneigatDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Sameeh A Al-SarayrehDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.
Mutah University · JOAl-Balqa Applied University · JOPublic Authority for Applied Education and Training · KWZarqa University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: Ovarian cancer is a leading cause of death in females. Since its treatment is challenging and causes severe side effects, novel therapies are urgently needed. One of the potential enzymes implicated in the progression of cancers is Cytochrome 4Z1 (CYP4Z1). Its expression in ovarian cancer remains unknown. Therefore, the current study aims to assess CYP4Z1 expression in different subtypes of ovarian cancers. Materials and Methods: Immunohistochemistry was used to characterize CYP4Z1 expression in 192 cases of ovarian cancers along with eight normal ovarian tissues. The enzyme’s association with various clinicopathological characteristics and survival was determined. Results: CYP4Z1 was strongly expressed in 79% of ovarian cancers, compared to negative expression in normal ovarian samples. Importantly, significantly high CYP4Z1 expres-sion was determined in patients with advanced-stage cancer and a high depth of invasion (p < 0.05). Surprisingly, CYP4Z1 expression was significantly associated with a low patient survival rate. Univariate analysis revealed that patient survival was strongly associated with CYP4Z1 expression, tumor stage, depth of invasion, and lymph node metastasis (p < 0.05). Multivariate analysis showed that only CYP4Z1 expression was significantly associated with patient survival (p < 0.05). Conclusions: CYP4Z1 expression is correlated with shorter patient survival and has been identified as an independent indicator of a poor prognosis for ovarian cancer patients.

Indexed as

Ovarian NeoplasmsCytochrome P450 Family 4FemaleHumansImmunohistochemistryPrognosisCYP4Z1 protein, humanCytochrome P450 Family 4cancerCytochrome 4Z1Cytochrome P450ImmunohistochemistryOvarian cancer

Identifiers

PMID36143940
PMCPMC9502355
OpenAlexW4296019156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.